FOR INVESTORS

Investors & Media

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Ardelyx's financial performance into perspective.

NASDAQ: ARDX

$4.60

- 0.35 (-7.07%)

4:00 PM ET on May 26, 2017

Delayed at least 20 minutes.

NEWS

May 12, 2017

Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C

FULL ARTICLE

May 5, 2017

Ardelyx Reports First Quarter 2017 Operating Results and Highlights Recent Progress

FULL ARTICLE

EVENTS & PUBLICATIONS

May 12, 2017 at 8:30 AM ET

Ardelyx Program Update

READ MORE

Mar 6, 2017 at 4:00 PM ET

Cowen and Company 37th Annual Healthcare Conference

READ MORE

Feb 15, 2017 at 8:30 AM ET

Ardelyx Clinical Update

READ MORE

RESOURCES